Maurer-Stroh Sebastian, Washietl Stefan, Eisenhaber Frank
Research Institute of Molecular Pathology, Dr Bohr-Gasse 7, A-1030 Vienna, Austria.
Genome Biol. 2003;4(4):212. doi: 10.1186/gb-2003-4-4-212. Epub 2003 Apr 1.
Three different protein prenyltransferases (farnesyltransferase and geranylgeranyltransferases I and II) catalyze the attachment of prenyl lipid anchors 15 or 20 carbons long to the carboxyl termini of a variety of eukaryotic proteins. Farnesyltransferase and geranylgeranyltransferase I both recognize a 'Ca1a2X' motif on their protein substrates; geranylgeranyltransferase II recognizes a different, non-CaaX motif. Each enzyme has two subunits. The genes encoding CaaX protein prenyltransferases are considerably longer than those encoding non-CaaX subunits, as a result of longer introns. Alternative splice forms are predicted to occur, but the extent to which each splice form is translated and the functions of the different resulting isoforms remain to be established. Farnesyltransferase-inhibitor drugs have been developed as anti-cancer agents and may also be able to treat several other diseases. The effects of these inhibitors are complicated, however, by the overlapping substrate specificities of geranylgeranyltransferase I and farnesyltransferase.
三种不同的蛋白质异戊二烯基转移酶(法尼基转移酶和香叶基香叶基转移酶I和II)催化将15或20个碳原子长的异戊二烯脂质锚连接到多种真核蛋白质的羧基末端。法尼基转移酶和香叶基香叶基转移酶I都识别其蛋白质底物上的“Ca1a2X”基序;香叶基香叶基转移酶II识别不同的非CaaX基序。每种酶都有两个亚基。由于内含子较长,编码CaaX蛋白质异戊二烯基转移酶的基因比编码非CaaX亚基的基因长得多。预计会出现可变剪接形式,但每种剪接形式的翻译程度以及不同的产生的异构体的功能仍有待确定。法尼基转移酶抑制剂药物已被开发用作抗癌剂,也可能能够治疗其他几种疾病。然而,由于香叶基香叶基转移酶I和法尼基转移酶的底物特异性重叠,这些抑制剂的作用变得复杂。